Deutsche Bank’s Oasmia Pharmaceutical AB OASM Stock Holding History

Deutsche Bank’s Portfolio OASM Stock Details OASM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,300	Closed	-$2K	–	5665
2019 Q1	$2K	Sell	1,300 -8,500	-87%	-$23.3K	﹤0.01%	5096
2018 Q4	$29K	Buy	+9,800	New	+$38.7K	﹤0.01%	4656
2016 Q3	–	Sell	-500	Closed	-$1K	–	5358
2016 Q2	$1K	Buy	+500	New	+$2.1K	﹤0.01%	5136

Other funds holding OASM

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Deutsche Bank's OASM Position: Q2 2019 in Review

Deutsche Bank sold out of Oasmia Pharmaceutical AB (OASM) in Q2 2019, closing a stake of 1,300 shares — an estimated $2K sold.

Deutsche Bank first reported a position in OASM in Q2 2016 and held it in 3 quarters. The position peaked at $29K in Q4 2018. 4 funds tracked by Wall St. Rank hold OASM as of Q2 2019.

Deutsche Bank reported no remaining Oasmia Pharmaceutical AB position as of Q2 2019 after selling out during the quarter.
Deutsche Bank sold 1,300 Oasmia Pharmaceutical AB shares in Q2 2019, an estimated $2K.
Deutsche Bank first reported a position in Oasmia Pharmaceutical AB in Q2 2016 and held it in 3 quarters.
Deutsche Bank's Oasmia Pharmaceutical AB position peaked at $29K in Q4 2018.
4 funds tracked by Wall St. Rank held Oasmia Pharmaceutical AB as of Q2 2019.

Based on Deutsche Bank's 13F filing for Q2 2019, filed 14 Aug 2019.